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Summary
Aims.We evaluated relaxin’s behaviour during a haemodialytic session and the effects of its 
intradialytic variability on blood pressure.
Methods. We enrolled 25 patients and evaluated relaxin’s levels during a haemodialytic session. 
We also dosed interdialytic relaxin and enrolled 10 healthy subjects and 16 patients with III 
stage chronic renal failure as controls.
Results. Haemodialyzed patients have relaxin’s baseline concentrations higher than healthy 
controls, but lower than chronic patients. During the treatment, relaxin is removed; it increases 
again throughout the interdialytic phase. Furthermore, relaxin’s pre- haemodialytic concentra-
tion positively and significantly correlates with systolic, diastolic, and mean BP; such correla-
tions disappear at the end of the treatment. 
Conclusion. Relaxin’s removal during the treatment may intervene in the pathogenesis of intra-
dialytic hypertension. Hence, relaxin could be not only a new biomarker but also an active 
player in the intradialytic variations of blood pressure.
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Relaxin is a 6 kDa-peptidic-hormone which plays a role in the renal and systemic 
haemodynamic changes of pregnancy3. It also exerts pleiotropic actions, particularly 
at the cardiovascular level1. We evaluated, for the first time, relaxin’s behaviour dur-
ing a haemodialytic (HD) session and the potential effects of its intradialytic variabili-
ty on arterial blood pressure (BP).
We recruited 25 patients (male/female, 10/15; mean age, 62.7±14 years; dialysis 
vintage in months, 36 [10-284]; residual GFR 2.3±0.6 ml/min) receiving dialytic treat-
ment, three times a week, with AFB (Acetate Free Biofiltration) technique. Blood 
samples were obtained from upstream of the haemodialyzer at the beginning and at 
the end of the session, and from downstream at the beginning. Relaxin’s serum lev-
els were assessed by the Human Relaxin-2 RIA Kit, Phoenix Pharmaceuticals, Inc®. 
All values were normalized to volume, considering haematocrit and serum albumin. 
We also dosed relaxin during the interdialytic period and enrolled 10 healthy subjects 
and 16 patients with III stage chronic renal failure (CRF) as controls.
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We observed that HD patients had relaxin’s baseline concentrations (pre-
HD, 20.81±17.86 pg/ml) significantly higher than healthy controls (2.28±2.19 pg/
ml,P<0.001), but lower than CRF patients (35.47±30.94 pg/ml,P=0.018). Through-
out the HD session, relaxin was removed (Fig.1) by the filter (from 20.81±17.86 to 
2.54±3.07 pg/ml,P<0.001); it increased again during the interdialytic phase (14.80±11.63 
pg/ml,P<0.001). Additionally, relaxin’s pre-HD concentration positively and signifi-
cantly correlated with systolic (r=0.72,P<0.0001), diastolic (r=0.61,P=0.0011), and mean 
(r=0.75,P<0.0001) BP; such correlations disappeared at the end of HD treatment. 
Relaxin induces vasodilatation, as already established2; hence, it is usually nega-
tively related to BP. Conversely, our data show a direct correlation between pre-HD 
relaxin and BP. The high baseline relaxin’s levels in HD patients could express a com-
pensatory mechanism to the increase in BP due to the fluid accumulation occurring 
between two consecutive HD sessions. The correlation between relaxin and BP is lost 
at the end of the treatment most likely because, during the HD session, the volume 
removal exerts a major role in influencing BP compared to that of vasoactive factors 
(endothelin-1, angiotensin II, relaxin, etc) in most patients. Contrariwise, in those sub-
jects who show a volume-independent intradialytic hypertension (about 8-15% of HD 
patients), relaxin’s removal by HD could play a significant role in determining BP’s 
increase. Thus, relaxin could be not only a new biomarker but also an active player in 
the intradialytic variations of BP.
References
1) Bani D. (2008) Relaxin as a natural agent for vascular health. Vasc Health Risk 
Manag. 4(3):515-24.
2) Conrad KP, Shroff SG. (2011) Effects of relaxin on arterial dilation, remodeling, 
and mechanical properties. Curr Hypertens Rep. 13(6):409-20.
3) McGuane JT, et al. (2009) Role of relaxin in maternal systemic and renal vascular 
adaptations during gestation. Ann N Y Acad Sci. 1160:304-312.
Figure 1. Relaxin’s behaviour during HD treatment.
